We are developing

a new generation of medicines

based on the human microbiome.

We provide new solutions based on the human microbiome for sufferers of serious chronic diseases for which there is currently no other therapy.

ABOUT US

Mikrobiomik

We are a bio-pharmaceutical company founded to conduct research into and develop medicines based on the human microbiome and provide new solutions in serious, chronic diseases for which there is currently no other therapy. We aspire to lead the paradigm shift entailed by designing therapeutic solutions based on the human microbiome and to be the first company in the world to market a medicine based on faecal microbiota in the EU.

Learn more
WE DEVELOP MEDICINES

C. difficile

C. difficile is the main pathogen responsible for acquired diarrhoea in hospitalised patients, which is known as C. difficile infection (CDI) and accounts for 20% of antibiotic-associated diarrhoea and colitis cases. The incidence of CDI has been increasing, both in hospitalised patients and in the community. This is partly due to the appearance of hypervirulent strains, but also to improvements in diagnostic methods and the sometimes non-rational use of antibiotics.

More information

Latest news

17/03/2022 in Corporativas

Seed Capital Bizkaia takes 3% stake in shares of Mikrobiomik

Seed Capital Bizkaia takes 3% stake in shares of Mikrobiomik. Under its remit to promote innovative business ventures, on 11 March Seed Capital Bizkaia acquired 3% of the shares of…
Read More
12/01/2022 in Corporate

Mikrobiomik on television

Mikrobiomik on TV. Last weekend we had the pleasure of appearing on the ETB programme Teknopolis. On this occasion and in a simple way, we explained to the public what…
Read More